Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 3, 2008, Pages 477-484

  Gregorc, V ^a   Hidalgo, M ^b   Spreafico, A ^a   Cusatis, G ^b   Ludovini, V ^c   Ingersoll, R G ^b   Marsh, S ^d   Steinberg, S M ^e   Vigano M G ^a   Ghio, D ^a   Villa, E ^a   Sparreboom, A ^e,f   Baker, S D ^b,f  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c POLICLINICO MONTELUCE   (Italy)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CISPLATIN; CYTOSINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; NAVELBINE; TAXANE DERIVATIVE; THYMINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DIARRHEA; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GERM LINE; HAPLOTYPE; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GERM-LINE MUTATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 39449096577     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100320     Document Type: Article

References (42)

1. Huisman, C., Smit, E.F., Giaccone, G. & Postmus, P.E. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J. Clin. Oncol. 18, 3722-3730 (2000).
2. Fossella, F.V. et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18, 2354-2362 (2000).
3. Hanna, N. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589-1597 (2004).
4. Shepherd, F.A. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, 2095-2103 (2000).
5. Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21, 2237-2246 (2003).
6. Kris, M.G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003).
7. Blackhall, F., Ranson, M. & Thatcher, N. Where next for gefitinib in patients with lung cancer? Lancet Oncol. 7, 499-507 (2006).
8. Shepherd, F.A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
9. Ho, C., Davies, A.M., Lara, P.N. Jr. & Gandara, D.R. Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. Clin. Lung Cancer 7 (suppl. 4), S118-S125 (2006).
10. Woodburn, J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 82, 241-250 (1999).
11. Raymond, E., Faivre, S. & Armand, J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 (suppl. 1), 15-23 (2000); discussion 41-42.
12. Janne, P.A. & Johnson, B.E. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 12, 4416s-4420s (2006).
13. Riely, G.J., Politi, K.A., Miller, V.A. & Pao, W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 12, 7232-7241 (2006).
14. Shigematsu, H. & Gazdar, A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 118, 257-262 (2006).
15. Chou, T.Y. et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 11, 3750-3757 (2005).
16. Rizvi, N.A. et al. A prospective study to correlate EGFR mutations with gefitinib response. Proc. Am. Soc. Clin. Oncol. 23, 643s (2005); abstract 7091.
17. Brandt, B., Meyer-Staeckling, S., Schmidt, H., Agelopoulos, K. & Buerger, H. Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin. Cancer Res. 12, 7252-7260 (2006).
18. Liu, W. et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 65, 46-53 (2005).
19. Nomura, M. et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 4, e125 (2007).
20. Buerger, H. et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res. 60, 854-857 (2000).
21. Gebhardt, F., Zanker, K.S. & Brandt, B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 274, 13176-13180 (1999).
22. Amador, M.L. et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 64, 9139-9143 (2004).
23. Liu, G. et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J March 20 (2007); [E-pub ahead of print].
24. Reck, M. & Gatzemeier, U. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib. Lung Cancer 50, 107-114 (2005).
25. Schutte, W., Nagel, S., Schaedlich, S., Brust, D. & Blankenburg, T. Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the "Iressa" expanded access program. Onkologie 28, 195-198 (2005).
26. Janne, P.A., Engelman, J.A. & Johnson, B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. 23, 3227-3234 (2005).
27. Han, S.W. et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenet. Genomics 17, 313-319 (2007).
28. Ichihara, S. et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int. J. Cancer 120, 1239-1247 (2007).
29. Mohamed, M.K., Ramalingam, S., Lin, Y., Gooding, W. & Belani, C.P. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann. Oncol. 16, 780-785 (2005).
30. Park, J. et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin. Cancer Res. 10, 4383-4388 (2004).
31. Dudek, A.Z., Kmak, K.L., Koopmeiners, J. & Keshtgarpour, M. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 51, 89-96 (2006).
32. Veronese, M.L. et al. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania. Cancer Invest. 23, 296-302 (2005).
33. Ono, M. & Kuwano, M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res. 12, 7242-7251 (2006).
34. Rosell, R., Taron, M., Reguart, N., Isla, D. & Moran, T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin. Cancer Res. 12, 7222-7231 (2006).
35. Ceresoli, G.L. et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann. Oncol. 15, 1042-1047 (2004).
36. Gregorc, V. et al. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 10, 6006-6012 (2004).
37. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216 (2000).
38. Cusatis, G. et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst. 98, 1739-1742 (2006).
39. Buerger, H. et al. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence - first results of an inter-ethnic breast cancer study. J. Pathol. 203, 545-550 (2004).
40. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50, 163-170 (1966).
41. Cox, D.R. Regression models and life tables. J. R. Stat. Soc. B 34, 187-202 (1972).
42. Simon, R. & Altman, D.G. Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer 69, 979-985 (1994).